Annual CFO
-$90.90 M
+$17.19 M+15.90%
31 December 2023
Summary:
Adverum Biotechnologies annual cash flow from operations is currently -$90.90 million, with the most recent change of +$17.19 million (+15.90%) on 31 December 2023. During the last 3 years, it has fallen by -$11.61 million (-14.64%). ADVM annual CFO is now -7074.59% below its all-time high of -$1.27 million, reached on 31 December 2012.ADVM Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$21.12 M
-$1.28 M-6.45%
30 September 2024
Summary:
Adverum Biotechnologies quarterly cash flow from operations is currently -$21.12 million, with the most recent change of -$1.28 million (-6.45%) on 30 September 2024. Over the past year, it has increased by +$2.79 million (+11.66%). ADVM quarterly CFO is now -468.85% below its all-time high of $5.73 million, reached on 30 June 2014.ADVM Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$85.54 M
+$2.79 M+3.16%
30 September 2024
Summary:
Adverum Biotechnologies TTM cash flow from operations is currently -$85.54 million, with the most recent change of +$2.79 million (+3.16%) on 30 September 2024. Over the past year, it has increased by +$2.51 million (+2.85%). ADVM TTM CFO is now -2887.26% below its all-time high of $3.07 million, reached on 30 June 2014.ADVM TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ADVM Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +15.9% | +11.7% | +2.9% |
| 3 y3 years | -14.6% | +18.1% | +17.9% |
| 5 y5 years | -68.5% | -121.7% | -81.8% |
ADVM Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -14.6% | +15.9% | -14.3% | +33.6% | at high | +25.9% |
| 5 y | 5 years | -84.9% | +15.9% | -121.7% | +37.7% | -81.8% | +25.9% |
| alltime | all time | -7074.6% | +15.9% | -468.9% | +37.7% | -2887.3% | +25.9% |
Adverum Biotechnologies Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$21.12 M(+6.5%) | -$85.54 M(-3.2%) |
| June 2024 | - | -$19.84 M(-14.6%) | -$88.33 M(-3.7%) |
| Mar 2024 | - | -$23.25 M(+9.0%) | -$91.73 M(+0.9%) |
| Dec 2023 | -$90.90 M(-15.9%) | -$21.33 M(-10.8%) | -$90.90 M(+3.2%) |
| Sept 2023 | - | -$23.91 M(+2.9%) | -$88.05 M(-8.2%) |
| June 2023 | - | -$23.25 M(+3.7%) | -$95.94 M(-5.5%) |
| Mar 2023 | - | -$22.41 M(+21.3%) | -$101.57 M(-6.0%) |
| Dec 2022 | -$108.09 M(+0.2%) | -$18.48 M(-41.9%) | -$108.09 M(-6.4%) |
| Sept 2022 | - | -$31.81 M(+10.1%) | -$115.43 M(+5.5%) |
| June 2022 | - | -$28.88 M(-0.2%) | -$109.42 M(-4.4%) |
| Mar 2022 | - | -$28.93 M(+12.1%) | -$114.45 M(+6.1%) |
| Dec 2021 | -$107.83 M(+36.0%) | -$25.82 M(+0.1%) | -$107.83 M(+3.4%) |
| Sept 2021 | - | -$25.80 M(-23.9%) | -$104.24 M(-0.7%) |
| June 2021 | - | -$33.91 M(+52.1%) | -$104.99 M(+19.3%) |
| Mar 2021 | - | -$22.30 M(+0.4%) | -$87.98 M(+11.0%) |
| Dec 2020 | -$79.29 M(+61.3%) | -$22.22 M(-16.3%) | -$79.29 M(+10.3%) |
| Sept 2020 | - | -$26.54 M(+57.0%) | -$71.90 M(+31.0%) |
| June 2020 | - | -$16.91 M(+24.2%) | -$54.89 M(+10.7%) |
| Mar 2020 | - | -$13.62 M(-8.2%) | -$49.57 M(+0.8%) |
| Dec 2019 | -$49.17 M(-8.9%) | -$14.84 M(+55.7%) | -$49.17 M(+4.5%) |
| Sept 2019 | - | -$9.53 M(-17.8%) | -$47.06 M(-13.5%) |
| June 2019 | - | -$11.59 M(-12.3%) | -$54.44 M(+0.4%) |
| Mar 2019 | - | -$13.22 M(+3.8%) | -$54.20 M(+0.4%) |
| Dec 2018 | -$53.96 M | -$12.73 M(-24.7%) | -$53.96 M(+1.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | -$16.90 M(+48.9%) | -$53.43 M(+14.9%) |
| June 2018 | - | -$11.35 M(-12.6%) | -$46.52 M(-0.2%) |
| Mar 2018 | - | -$12.98 M(+6.4%) | -$46.59 M(+2.6%) |
| Dec 2017 | -$45.42 M(+18.4%) | -$12.20 M(+22.2%) | -$45.42 M(+9.3%) |
| Sept 2017 | - | -$9.98 M(-12.6%) | -$41.56 M(+0.8%) |
| June 2017 | - | -$11.42 M(-3.4%) | -$41.23 M(+8.4%) |
| Mar 2017 | - | -$11.82 M(+41.7%) | -$38.03 M(-0.9%) |
| Dec 2016 | -$38.37 M(+8.6%) | -$8.34 M(-13.5%) | -$38.37 M(-2.0%) |
| Sept 2016 | - | -$9.65 M(+17.3%) | -$39.15 M(+1.1%) |
| June 2016 | - | -$8.22 M(-32.3%) | -$38.72 M(-2.6%) |
| Mar 2016 | - | -$12.15 M(+33.2%) | -$39.75 M(+12.5%) |
| Dec 2015 | -$35.34 M(+525.7%) | -$9.13 M(-1.0%) | -$35.34 M(+13.0%) |
| Sept 2015 | - | -$9.22 M(-0.3%) | -$31.27 M(+15.7%) |
| June 2015 | - | -$9.25 M(+19.5%) | -$27.02 M(+124.4%) |
| Mar 2015 | - | -$7.74 M(+53.2%) | -$12.04 M(+113.2%) |
| Dec 2014 | -$5.65 M(+159.7%) | -$5.05 M(+1.6%) | -$5.65 M(+329.8%) |
| Sept 2014 | - | -$4.97 M(-186.8%) | -$1.31 M(-142.8%) |
| June 2014 | - | $5.73 M(-525.2%) | $3.07 M(-190.9%) |
| Mar 2014 | - | -$1.35 M(+86.8%) | -$3.38 M(+55.3%) |
| Dec 2013 | -$2.17 M(+71.7%) | -$721.00 K(+22.2%) | -$2.17 M(+49.6%) |
| Sept 2013 | - | -$590.00 K(-18.1%) | -$1.45 M(+68.3%) |
| June 2013 | - | -$720.00 K(+400.0%) | -$864.00 K(+500.0%) |
| Mar 2013 | - | -$144.00 K | -$144.00 K |
| Dec 2012 | -$1.27 M | - | - |
FAQ
- What is Adverum Biotechnologies annual cash flow from operations?
- What is the all time high annual CFO for Adverum Biotechnologies?
- What is Adverum Biotechnologies annual CFO year-on-year change?
- What is Adverum Biotechnologies quarterly cash flow from operations?
- What is the all time high quarterly CFO for Adverum Biotechnologies?
- What is Adverum Biotechnologies quarterly CFO year-on-year change?
- What is Adverum Biotechnologies TTM cash flow from operations?
- What is the all time high TTM CFO for Adverum Biotechnologies?
- What is Adverum Biotechnologies TTM CFO year-on-year change?
What is Adverum Biotechnologies annual cash flow from operations?
The current annual CFO of ADVM is -$90.90 M
What is the all time high annual CFO for Adverum Biotechnologies?
Adverum Biotechnologies all-time high annual cash flow from operations is -$1.27 M
What is Adverum Biotechnologies annual CFO year-on-year change?
Over the past year, ADVM annual cash flow from operations has changed by +$17.19 M (+15.90%)
What is Adverum Biotechnologies quarterly cash flow from operations?
The current quarterly CFO of ADVM is -$21.12 M
What is the all time high quarterly CFO for Adverum Biotechnologies?
Adverum Biotechnologies all-time high quarterly cash flow from operations is $5.73 M
What is Adverum Biotechnologies quarterly CFO year-on-year change?
Over the past year, ADVM quarterly cash flow from operations has changed by +$2.79 M (+11.66%)
What is Adverum Biotechnologies TTM cash flow from operations?
The current TTM CFO of ADVM is -$85.54 M
What is the all time high TTM CFO for Adverum Biotechnologies?
Adverum Biotechnologies all-time high TTM cash flow from operations is $3.07 M
What is Adverum Biotechnologies TTM CFO year-on-year change?
Over the past year, ADVM TTM cash flow from operations has changed by +$2.51 M (+2.85%)